In Brief: Advertising Regulation, Vansen Consumer, Star Scientific
This article was originally published in The Tan Sheet
Executive Summary
Supplement firms’ claims referred to FDA, FTC; review prompts new script for Zvelt ads; Vansen starts consumer portfolio with Canadian deal; Star Scientific pivots to drug development; and more In Brief.
You may also be interested in...
Star Scientific IND Blocks Supplement Marketing Options – FDA
An FDA warning letter deems Star Scientific’s CigRx and Anatabloc supplements unapproved drugs due to multiple issues, including claims. The firm’s approved IND study for the ingredient also prevents its use in supplements, the agency says.
Therapeutic Product Regulatory Reforms Considered Down Under
Australia's Therapeutic Goods Association plans to implement a number of regulations to update and streamline the existing framework for over-the-counter and prescription drugs as well as medical devices
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.